Phase II Study: Antineoplastons in Anaplastic Astrocytoma | Burzynski

Recurrent anaplastic astrocytoma is a challenging brain tumor that often returns after standard treatments such as surgery, radiation, and chemotherapy. This tumor type is aggressive, progresses rapidly, and is often resistant to conventional therapies, making the exploration of investigational approaches critical for advancing understanding and patient care.

Understanding Antineoplastons

Antineoplastons are naturally occurring peptides and amino acid derivatives developed by Dr. Stanislaw Burzynski to target the genetic drivers of cancer. Unlike conventional therapies, they aim to address the underlying mechanisms of tumor growth.

In the Phase II study, A10 and AS2‑1 were administered approximately every four hours over a median of 23 weeks. Patients were closely monitored for tumor response, treatment tolerance, and overall quality of life. At the Burzynski Clinic, these therapies are part of personalized treatment plans tailored to each patient’s needs, combining effectiveness with minimized side effects.

Clinical Research and Investigational Therapies

To explore new options for patients with recurrent anaplastic astrocytoma, the Burzynski Clinic conducted a Phase II clinical study investigating the use of antineoplastons A10 and AS2‑1. This study evaluated the administration, safety, and observed outcomes of these investigational compounds in adults with limited conventional treatment options.

Clinical research like this is essential for advancing cancer care. Participating in trials allows patients to access investigational therapies while contributing to the broader understanding of emerging treatments.

Published in Cancer and Clinical Oncology, the Phase II study included 27 adult patients (ages 19–57), all of whom had previously undergone surgery and radiation, and 16 of whom had also received chemotherapy. Outcomes reported in the study included:

• Complete response: 7% of patients
• Partial response: 11%
• Stable disease: 22%
• 12-month survival: Progression-free 26%, overall 41%
• Safety: Only serious toxicity was reversible Grade 3 hypokalemia in 7% of participants; no chronic toxicities reported
• Quality of life: Remained largely stable throughout the study

These results highlight careful monitoring and structured study design while emphasizing that outcomes may vary and are not guaranteed.

The Role of Clinical Research

Key aspects of clinical research include:

• Structured evaluation: Therapies are administered and monitored in a controlled environment.
• Clear study guidance: Participants receive information about procedures, goals, and expectations.
• Opportunity to contribute: Data from studies informs future research and enhances understanding of potential therapies.

Engaging in clinical research supports both individual patient care and the advancement of oncology as a whole.

Personalized Care at the Burzynski Clinic

At the Burzynski Clinic in Houston, Texas, Dr. Stanislaw Burzynski and his team deliver care that reflects each patient’s unique medical history, tumor characteristics, and overall health. Treatment plans are tailored to individual needs and include careful monitoring, documentation, and supportive services.

The clinic integrates research on investigational compounds such as antineoplastons with patient-centered support, reflecting a broader movement in oncology toward personalized medicine. This approach emphasizes treatments and strategies that consider each patient’s circumstances, goals, and overall well-being.'

Holistic and Supportive Care During Treatment

Cancer treatment affects not only the body but also the mind and emotional well-being of patients and their families. At the Burzynski Clinic, care extends beyond medical therapies to include holistic support strategies that help patients maintain strength, resilience, and quality of life throughout their treatment journey.

Supportive care can include:

• Nutrition guidance: Personalized plans to help maintain energy, support immune function, and manage treatment-related side effects.

• Gentle exercise and movement: Activities designed to preserve strength, flexibility, and overall wellness during therapy.

• Stress management and mindfulness: Techniques such as meditation, deep breathing, or journaling can reduce anxiety and promote emotional balance.

• Patient and caregiver education: Clear explanations of treatment plans, potential side effects, and strategies to navigate daily life during therapy.

By integrating these holistic approaches with investigational therapies like antineoplastons, patients are empowered to take an active role in their care. Emotional and physical well-being are prioritized alongside treatment goals, supporting a comprehensive, patient-centered experience.

Broader Significance of Investigational Studies

Investigational therapies like A10 and AS2‑1 offer insights into alternative strategies for recurrent anaplastic astrocytoma. Early-phase studies with limited participants provide valuable data on administration, tolerability, and observed outcomes. These studies help guide future clinical trials and inform how investigational therapies may be incorporated into personalized care plans.

Taking the Next Step

For adults facing recurrent anaplastic astrocytoma, staying informed about ongoing research can help guide decisions about care. The Burzynski Clinic in Houston, Texas, led by Dr. Stanislaw Burzynski, conducts research on investigational compounds such as antineoplastons. Reviewing published studies and emerging research offers patients and caregivers insights into potential treatment options.

Book a consultation today to speak with Dr. Burzynski and his team, discuss your individual situation, and explore options for personalized care and support at the Burzynski Clinic.